UK centre seeks wider pre-implantation testing:
This article was originally published in Clinica
Executive Summary
London's Bridge Fertility, Gynaecology and Genetics Centre is planning to apply for a licence to use isothermal whole genome amplification in pre-implantation testing. It says that the technique would enable it to screen for "hundreds of conditions" within days of fertilisation. At present, pre-implantation genetic screening, which is regulated by the Human Fertilisation and Embryology Authority (HFEA), can only be performed on a small number of disorders, such as cystic fibrosis, muscular dystrophy and haemophilia. "Centres must submit an application to the HFEA for each new condition for which they wish to test and for each new test that they wish to use," according to current HFEA guidelines, issued in 2001.
You may also be interested in...
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.
GE HealthCare Launches AI-Powered Voluson Ultrasound For Women’s Health
Voluson Signature 20 and 18 ultrasound provides clinicians with workflow efficiencies in detecting female reproductive health problems, especially those related to pregnancy.